Cediranib + Olaparib for Ovarian and Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing the combination of two drugs, cediranib maleate and olaparib, to treat patients with certain types of recurrent cancer. Cediranib maleate cuts off the blood supply to cancer cells, while olaparib stops them from repairing their DNA. The trial aims to find the best dose and see if the combination works better than using olaparib by itself. Combining cediranib, which cuts off the blood supply to cancer cells, with olaparib, which stops cancer cells from repairing their DNA, may help patients live longer without their cancer getting worse.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot take certain medications that strongly affect liver enzymes (CYP3A4). You should discuss your current medications with the trial team to see if any adjustments are needed.
Is the combination of Cediranib and Olaparib safe for humans?
How is the drug combination of Cediranib and Olaparib unique for treating ovarian and breast cancer?
The combination of Cediranib and Olaparib is unique because it combines an anti-angiogenic drug (Cediranib) that blocks blood vessel growth with a PARP inhibitor (Olaparib) that prevents cancer cells from repairing their DNA, potentially improving progression-free survival in ovarian cancer compared to using Olaparib alone.12367
What data supports the effectiveness of the drug combination Cediranib and Olaparib for ovarian cancer?
Who Is on the Research Team?
Joyce Liu, MD
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
This trial is for adults with recurrent ovarian, fallopian tube, peritoneal cancer or triple-negative breast cancer. Participants must have had platinum-based chemotherapy (for ovarian cancer), be able to monitor their blood pressure daily, and not have used certain other treatments before. They should be in good health otherwise, with a life expectancy over 6 months and no severe uncontrolled conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Phase I
Patients receive cediranib maleate and olaparib to determine the maximum tolerated dose. Cycles repeat every 28 days.
Treatment Phase II
Randomized treatment with either cediranib maleate and olaparib or olaparib alone. Cycles repeat every 28 days.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion.
What Are the Treatments Tested in This Trial?
Interventions
- Cediranib Maleate
- Olaparib
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor